查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014718

組蛋白去乙醯化酶抑制劑市場：2026-2032年全球市場預測（按藥物類別、給藥途徑、分銷管道、適應症和最終用戶分類）

Histone Deacetylase Inhibitors Market by Drug Class, Route of Administration, Distribution Channel, Therapeutic Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，組蛋白去乙醯化酶抑制劑市場價值將達到 13.4 億美元，到 2026 年將成長至 14.4 億美元，到 2032 年將達到 22.3 億美元，複合年成長率為 7.53%。

主要市場統計數據
基準年 2025 13.4億美元
預計年份：2026年 14.4億美元
預測年份 2032 22.3億美元
複合年成長率 (%) 7.53%

闡明推動組蛋白去乙醯化酶抑制劑發展的策略挑戰和臨床潛力以及市場動態的演變。

隨著我們對表觀遺傳機制及其在多種疾病治療應用方面的理解不斷加深，組蛋白去乙醯化酶（HDAC）抑制劑領域正處於轉折點。過去十年，分子生物學和化學的進步使得設計更具選擇性的抑制劑成為可能，從而獲得了療效更佳且脫靶效應最小的抑制劑。因此，目前的研究管線包括能夠精確調控特定HDAC異構體的化合物，為下一代治療方法鋪平了道路。

從分子設計創新到臨床應用突破，找出正在革新組蛋白去乙醯化酶抑制劑研發的關鍵進展。

近年來，HDAC抑制劑的研發發生了變革性轉變，這主要得益於異構體選擇性化合物的出現，這些化合物拓寬了治療選擇。靶向I類、II類、III類和IV類HDAC的分子作為下一個前沿領域備受關注，從HDAC1到HDAC11，甚至包括sirtuin家族成員，每個異構體組都展現出獨特的疾病調控特性。這種精準調控的趨勢得益於高通量篩檢技術和結構導向設計，這些技術能夠識別出具有最佳結合親和性和安全性的先導化合物。

分析美國新關稅對供應鏈、製造成本和全球藥品取得的廣泛影響。

美國在2025年實施的新關稅將為組蛋白去乙醯化酶抑制劑的供應鏈和生產策略帶來新的複雜性。對某些活性藥物成分和特殊原料徵收的進口關稅增加了依賴海外採購的製造商的生產成本。因此，許多企業正在重新審視其供應商組合，並更加重視近岸外包和國內夥伴關係，以減輕關稅波動的影響。

透過解讀市場區隔趨勢，可以發現不同藥物類別、給藥途徑和治療領域的針對性機會。

對細分市場的深入理解揭示了不同藥物類別中存在的定向成長機會，每個類別都有其獨特的開發路徑和治療前景。針對 I 型至 IV 型亞型的異構體異構體HDAC 抑制劑與通用型 HDAC 分子同步發展，旨在調節 HDAC1、HDAC2、HDAC3、HDAC8、HDAC4、HDAC5、HDAC6、HDAC7、Sirtuin 1、Sirtuin 2、Sirtuin 3 和 HDAC11 等特定靶點，從而應用差異化臨床。這種分層也需考慮給藥途徑。靜脈製劑持續滿足急性治療的需求，而口服療法則支持慢性治療方案並提高患者的便利性。

透過明確區域差異，美洲、歐洲、中東和非洲以及亞太市場的成長要素和挑戰將更加清晰。

區域分析揭示了美洲、歐洲、中東和非洲以及亞太市場各自獨特的成長要素和挑戰，每個市場都具有獨特的醫療基礎設施、法規結構和患者群體特徵。在美洲，對生物技術中心的大力投資和支持性的專利政策正在加速從基礎研究到臨床應用的轉化，同時對創新腫瘤和神經系統疾病療法的需求仍然強勁。支付方的成本控制措施和不斷演變的報銷模式正在推動臨床和經濟價值的清晰展現。

本文重點介紹了在 HDAC 抑制劑領域推動創新、策略聯盟和競爭地位的產業先驅領導者。

主要企業透過合作研究、策略性收購和有針對性的產品線拓展，不斷突破HDAC抑制劑創新的界限。成熟的製藥公司憑藉其豐富的臨床試驗經驗和全球商業化網路，推動後期候選藥物的研發；而生物技術公司和研究機構則主導早期藥物發現工作，專注於新型化學結構和以生物標記主導的開發方案。

可行的策略能夠幫助產業相關人員克服監管方面的複雜性，最佳化研發管線優先級，並加快市場進入速度。

為了因應不斷變化的監管和經濟環境，產業相關人員應優先考慮在研發早期階段整合轉化生物標記，以支持快速核准途徑並提升提案價值。建立異構體選擇性化合物檢驗卓越中心可以簡化知識共用並促進跨學科創新。企業也應評估雙途徑給藥策略，在慢性病治療中口服給藥的便利性與急性情況下靜脈注射的精準性之間取得平衡，從而最大限度地提高產品組合的適應能力。

嚴謹的多模態研究框架，整合了專家訪談、二手資料和可靠的檢驗方案。

本研究採用嚴謹的多模態方法，整合了專家訪談、二手資料和檢驗研討會，以確保獲得全面且準確的見解。主要資訊是透過與表觀遺傳學領域的關鍵意見領袖（KOL）、臨床開發專家、監管專家和商業策略專家進行結構化討論收集的。這些定性觀點與同行評審期刊、專利申請、會議論文集和行業出版物等二級資訊來源進行了交叉比對。

關鍵見解的整合突顯了相關人員在利用 HDAC 抑制劑的潛力並克服市場障礙方面面臨的策略挑戰。

組蛋白去乙醯化酶抑制劑的策略發展軌跡凸顯了科學創新、不斷變化的調節環境和市場進入考量之間的動態互動。隨著異構體選擇性化合物和先進製劑推動產品差異化，制定穩健的轉化策略和建立有針對性的夥伴關係關係至關重要。外部壓力，特別是不斷變化的關稅體系，要求企業採用靈活的供應鏈模式和成本管理機制，以確保獲利能力和供應的連續性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 組蛋白去乙醯化酶抑制劑市場：依藥物類別分類

  • 異構體選擇性HDAC抑制劑
    • 一級
      • HDAC1抑制劑
      • HDAC2抑制劑
      • HDAC3抑制劑
      • HDAC8抑制劑
    • 二類
      • HDAC4抑制劑
      • HDAC5抑制劑
      • HDAC6抑制劑
      • HDAC7抑制劑
    • 三級
      • Sirtuin 1 抑制劑
      • Sirtuin 2 抑制劑
      • Sirtuin 3 抑制劑
    • 四級
      • HDAC11抑制劑
  • 泛組蛋白去乙醯化酶抑制劑

第9章 組蛋白去乙醯化酶抑制劑市場：依給藥途徑分類

  • 靜脈注射（IV）
  • 口服

第10章 組蛋白去乙醯化酶抑制劑市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 依治療適應症分類的組蛋白去乙醯化酶抑制劑市場

  • 癌症
    • 血癌
      • 白血病
      • 淋巴瘤
      • 多發性骨髓瘤
    • 固體癌
      • 乳癌
      • 肺癌
      • 攝護腺癌
  • 發炎性疾病
    • 發炎性腸道疾病
    • 類風濕性關節炎
  • 神經系統疾病
    • 阿茲海默症
    • 帕金森氏症

第12章 組蛋白去乙醯化酶抑制劑市場：依最終用戶分類

  • 診所
  • 醫院
  • 研究機構

第13章 組蛋白去乙醯化酶抑制劑市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 組蛋白去乙醯化酶抑制劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 組蛋白去乙醯化酶抑制劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國組蛋白去乙醯化酶抑制劑市場

第17章：中國組蛋白去乙醯化酶抑制劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AstraZeneca plc
  • Bio-Techne Corporation
  • Bristol Myers Squibb Company
  • Curis Inc.
  • Eisai Co. Ltd.
  • Huya Bioscience International LLC
  • Italfarmaco SpA
  • Karyopharm Therapeutics Inc.
  • Karyopharm Therapeutics Inc.
  • Medivir AB
  • MEI Pharma Inc.
  • Merck KGaA
  • Novartis AG
  • Shenzhen Chipscreen Biosciences Co., Ltd.
  • Shuttle Pharma
  • Syndax Pharmaceuticals Inc.
  • Thermo Fisher Scientific, Inc.
  • Tokyo Chemical Industry Pvt. Ltd.
  • Xynomic Pharmaceuticals
Product Code: MRR-437E9896A56B

The Histone Deacetylase Inhibitors Market was valued at USD 1.34 billion in 2025 and is projected to grow to USD 1.44 billion in 2026, with a CAGR of 7.53%, reaching USD 2.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.34 billion
Estimated Year [2026] USD 1.44 billion
Forecast Year [2032] USD 2.23 billion
CAGR (%) 7.53%

Unveiling the Strategic Imperatives and Clinical Potential Driving the Evolution of Histone Deacetylase Inhibitor Development and Market Dynamics

The histone deacetylase inhibitor landscape stands at an inflection point, driven by an expanding understanding of epigenetic mechanisms and their therapeutic applications across a spectrum of diseases. Over the past decade, advances in molecular biology and chemistry have enabled the design of more selective inhibitors, refining efficacy profiles while minimizing off-target effects. As a result, research pipelines now feature compounds that precisely modulate specific HDAC isoforms, paving the way for next-generation interventions.

Regulatory agencies have responded to these innovations by streamlining approval pathways for targeted therapies, recognizing their potential to address unmet clinical needs. This environment has catalyzed renewed interest from both established pharmaceutical companies and emerging biotechs. Investment trends indicate a shift toward strategic partnerships that combine early-stage research capabilities with late-stage development expertise, fostering collaborative models that accelerate time to market without compromising scientific rigor.

The convergence of precision medicine, improved biomarker identification, and sophisticated screening platforms has created a fertile ground for pipeline diversification. As competition intensifies and patent landscapes evolve, stakeholders must stay attuned to the interplay between scientific breakthroughs and regulatory developments. This introduction sets the stage for a deep dive into the transformative shifts, external pressures, segmentation dynamics, regional nuances, competitive movements, and strategic imperatives shaping the future of histone deacetylase inhibitors.

Identifying Critical Advances Disrupting Histone Deacetylase Inhibitor R&D from Molecular Design Innovations to Clinical Application Breakthroughs

Recent years have witnessed transformative shifts in HDAC inhibitor research and development, characterized by the rise of isoform-selective compounds that offer enhanced therapeutic windows. Class I, Class II, Class III, and Class IV targeting molecules have garnered attention as the next frontier, with each isoform subset-ranging from HDAC1 through HDAC11 and sirtuin family members-presenting unique disease modulation profiles. This trend toward precision modulation has been propelled by high-throughput screening technologies and structure-guided design, which enable the identification of lead candidates with optimal binding affinities and safety margins.

Parallel advances in formulation science have improved drug delivery, enabling both oral and intravenous modalities to achieve sustained target engagement and favorable pharmacokinetics. Oral formulations are particularly compelling for chronic indications, while intravenous options maintain prominence in acute or hospital-based settings. Additionally, partnerships between academic institutions and industry have expedited the translation of preclinical findings into clinical trials, fostering a collaborative ecosystem that balances risk and reward.

Psychiatric and neurological disorders are emerging as promising indications alongside oncology and inflammatory diseases, driven by compelling preclinical data. As translational research bridges laboratory discoveries with patient-centric outcomes, stakeholders must navigate complex intellectual property landscapes and evolving safety expectations. These transformative shifts underscore the importance of integrated development strategies that align scientific innovation with market access realities.

Analyzing the Far-Reaching Implications of New United States Tariffs on Supply Chains Manufacturing Costs and Global Drug Accessibility

The implementation of new United States tariffs in 2025 introduces a layer of complexity for histone deacetylase inhibitor supply chains and manufacturing strategies. Import duties on certain active pharmaceutical ingredients and specialized raw materials have elevated production costs for manufacturers relying on overseas sourcing. As a result, many organizations are reevaluating supplier portfolios, with a growing emphasis on nearshoring and domestic partnerships to mitigate exposure to fluctuating tariff rates.

These cost pressures ripple through procurement, quality assurance, and logistics operations, compelling industry leaders to adopt leaner inventory practices and strategic hedging. Companies with vertically integrated capabilities find themselves at an advantage, leveraging in-house synthesis and formulation assets to shield their pipelines from abrupt cost surges. Meanwhile, mid-sized enterprises are exploring contract development and manufacturing organizations based domestically to preserve margin integrity and ensure continuity of supply.

Beyond operational adjustments, the tariff landscape has prompted reexamination of pricing strategies and reimbursement negotiations. Payers and healthcare providers are vigilant about cost trajectories, underscoring the need for clear value demonstrations. As stakeholders adapt to this new economic milieu, agility in sourcing and an integrated approach to cost management will serve as critical differentiators, shaping competitive positioning and long-term sustainability.

Decoding Market Segmentation Dynamics Reveals Targeted Opportunities Across Drug Class Administration Channels and Therapeutic Areas

A nuanced understanding of segmentation unveils targeted growth opportunities across distinct drug classes, each with its own development trajectory and therapeutic promise. Isoform-selective HDAC inhibitors that focus on Class I through Class IV subsets are advancing alongside pan-HDAC molecules, with efforts to modulate specific targets such as HDAC1, HDAC2, HDAC3, HDAC8, HDAC4, HDAC5, HDAC6, HDAC7, sirtuin1, sirtuin2, sirtuin3, and HDAC11 driving differentiated clinical profiles. This stratification is complemented by consideration of administration routes; intravenous formulations continue to address acute care needs, while oral therapies support chronic dosing regimens and improve patient convenience.

Distribution channel dynamics further shape access and adoption patterns. Hospital pharmacies remain pivotal for inpatient and specialty care delivery, while online pharmacies offer novel pathways for patient-centric fulfillment. Traditional retail pharmacies serve as a critical interface for broader community uptake. Therapeutic indication segmentation highlights oncology as a flagship area, covering both hematological cancers-leukemia, lymphoma, multiple myeloma-and solid tumors such as breast, lung, and prostate cancers. Inflammatory conditions, including inflammatory bowel disease and rheumatoid arthritis, alongside neurological targets like Alzheimer's and Parkinson's diseases, expand the clinical horizon. End users vary from clinics managing day-to-day administration to hospitals overseeing complex regimens, and research institutes driving discovery through preclinical and translational studies.

Collectively, these segmentation pillars inform strategic portfolio design, channel optimization, and patient engagement models. By aligning development priorities with granular patient and provider needs, organizations can unlock differentiated value propositions and address unmet demands across therapeutic landscapes.

Unraveling Regional Variations Highlights Growth Drivers and Challenges Across Americas Europe Middle East Africa and Asia Pacific Markets

Regional insights reveal distinct drivers and challenges across Americas, Europe Middle East Africa, and Asia Pacific markets, each characterized by unique healthcare infrastructure, regulatory frameworks, and patient demographics. In the Americas, strong investment in biotechnology hubs and supportive patent policies foster rapid progression from bench to bedside, while demand for innovative oncology and neurology therapies remains high. Cost containment efforts by payers and evolving reimbursement models encourage clear demonstration of clinical and economic value.

Europe, the Middle East, and Africa exhibit varied market access pathways, with centralized approval mechanisms coexisting alongside country-specific pricing negotiations. This region benefits from well-established clinical trial networks and advanced healthcare systems, though cost-control measures and diverse regulatory requirements necessitate strategic alignment of clinical evidence generation and pricing policies. Emerging markets within the region also present growth prospects, driven by rising healthcare expenditure and expanding patient awareness.

In Asia Pacific, rapid industrialization and growing middle-class populations fuel demand for both oncology and inflammatory disorder treatments. Regulatory harmonization initiatives and accelerated approval schemes are gaining traction, facilitating faster entry of novel therapies. Manufacturing capacity expansion in key countries supports global supply, though complexities around intellectual property protection and price sensitivity require nuanced strategies. By acknowledging regional nuances and adapting market entry approaches accordingly, stakeholders can optimize resource allocation, engagement tactics, and value communication to maximize impact across diverse geographies.

Spotlighting Pioneering Industry Leaders Driving Innovation Strategic Collaborations and Competitive Positioning in the HDAC Inhibitor Domain

Leading organizations continue to push the boundaries of HDAC inhibitor innovation through collaborative research, strategic acquisitions, and targeted pipeline expansion. Established pharmaceutical companies leverage their extensive clinical trial expertise and global commercialization networks to advance late-stage candidates, while biotechnology firms and research institutes spearhead early discovery efforts, focusing on novel chemical scaffolds and biomarker-driven development plans.

Recent strategic alliances bridge therapeutic focus areas, such as combining HDAC inhibitors with immuno-oncology agents or pairing them with targeted therapies in neurological disorders. These partnerships underscore the importance of complementary expertise and resource sharing in accelerating timelines and managing risk. In parallel, selective licensing agreements enable smaller players to capitalize on larger entities' regulatory and manufacturing capabilities, creating a dynamic ecosystem where agility and scale coexist.

Investment in digital health and AI-driven analytics is also reshaping competitive landscapes. Companies that integrate real-world evidence platforms and advanced data modeling gain stronger insights into patient stratification, safety profiling, and market needs. As precision medicine becomes a core pillar of clinical development, organizations with robust data infrastructure and cross-functional collaboration models are positioned to lead the next wave of HDAC inhibitor therapeutics.

Actionable Strategies Empower Industry Stakeholders to Navigate Regulatory Complexities Optimize Pipeline Priorities and Accelerate Market Entry

To navigate evolving regulatory and economic environments, industry stakeholders should prioritize integration of translational biomarkers early in development programs to support accelerated approval pathways and strengthen value propositions. Establishing centers of excellence for isoform-selective compound validation can streamline knowledge sharing and foster cross-disciplinary innovation. Companies should also evaluate dual-route administration strategies, balancing oral convenience for chronic care with intravenous precision in acute settings to maximize portfolio resilience.

Cost management will require robust supply chain diversification; stakeholders are advised to cultivate relationships with domestic synthesis partners and leverage contract manufacturing specialists to mitigate tariff-related risks. Simultaneously, aligning evidence generation with health technology assessment expectations can facilitate favorable reimbursement outcomes, especially in value-driven payment environments.

Regional market leaders should tailor launch models to local ecosystem dynamics, deploying targeted engagement programs for payers, clinicians, and patient advocacy groups. Collaborations with digital health providers can enhance patient adherence and real-world data collection, reinforcing long-term therapeutic value. Lastly, forging strategic alliances that link HDAC inhibition with complementary modalities-such as immunotherapies or neuroprotective agents-will differentiate pipelines and unlock novel combination approaches, creating sustainable competitive advantage.

Rigorous Multimodal Research Framework Integrating Primary Expert Consultations Secondary Data Synthesis and Robust Validation Protocols

This research employs a rigorous multimodal methodology, integrating primary expert interviews, secondary data synthesis, and validation workshops to ensure comprehensive and accurate insights. Primary input was gathered through structured discussions with key opinion leaders in epigenetics, clinical development professionals, regulatory affairs specialists, and commercial strategy experts. These qualitative perspectives were triangulated with secondary sources, including peer-reviewed journals, patent filings, conference proceedings, and industry publications.

Quantitative foundations were established by analyzing clinical trial registries, drug approval databases, and detailed supply chain cost analyses, without inferring specific market forecasts. Validation workshops convened cross-functional stakeholders to challenge assumptions, refine segmentation frameworks, and corroborate regional dynamics. The research framework prioritizes transparency, with all data sources and methodological steps documented for reproducibility.

Through iterative synthesis and peer review, the study delivers nuanced understanding of HDAC inhibitor R&D trajectories, manufacturing considerations, regulatory environments, segmentation nuances, and competitive landscapes. This approach ensures that conclusions and recommendations rest on a solid evidentiary base, enabling stakeholders to make informed strategic decisions.

Synthesis of Key Insights Emphasizes Strategic Imperatives for Stakeholders to Harness HDAC Inhibitor Potential and Overcome Market Barriers

The strategic trajectory of histone deacetylase inhibitors underscores a dynamic interplay between scientific innovation, regulatory evolution, and market access considerations. As isoform-selective compounds and advanced formulations drive differentiation, the need for robust translational strategies and targeted partnerships becomes paramount. External pressures, notably evolving tariff regimes, demand agile supply chain models and cost-control mechanisms to safeguard margins and continuity of supply.

Segmentation analysis highlights the importance of aligning development programs with specific patient needs, whether in oncology, inflammatory disorders, or neurological indications. Regionally tailored approaches are essential to navigate diverse regulatory landscapes and optimize launch configurations. Industry leaders must also embrace digital tools and data-driven decision making to enhance clinical trial efficiency, real-world evidence generation, and patient engagement.

By synthesizing insights across landscape shifts, segmentation dynamics, regional variations, and competitive actions, stakeholders can refine their strategic roadmaps, prioritize high-impact opportunities, and mitigate key risks. This comprehensive perspective lays the groundwork for sustained innovation and value creation in the evolving HDAC inhibitor domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Histone Deacetylase Inhibitors Market, by Drug Class

  • 8.1. Isoform-Selective HDAC Inhibitors
    • 8.1.1. Class I
      • 8.1.1.1. HDAC1 Inhibitors
      • 8.1.1.2. HDAC2 Inhibitors
      • 8.1.1.3. HDAC3 Inhibitors
      • 8.1.1.4. HDAC8 Inhibitors
    • 8.1.2. Class II
      • 8.1.2.1. HDAC4 Inhibitors
      • 8.1.2.2. HDAC5 Inhibitors
      • 8.1.2.3. HDAC6 Inhibitors
      • 8.1.2.4. HDAC7 Inhibitors
    • 8.1.3. Class III
      • 8.1.3.1. Sirtuin1 Inhibitors
      • 8.1.3.2. Sirtuin2 Inhibitors
      • 8.1.3.3. Sirtuin3 Inhibitors
    • 8.1.4. Class IV
      • 8.1.4.1. HDAC11 Inhibitors
  • 8.2. Pan-HDAC Inhibitors

9. Histone Deacetylase Inhibitors Market, by Route of Administration

  • 9.1. Intravenous (IV)
  • 9.2. Oral

10. Histone Deacetylase Inhibitors Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Histone Deacetylase Inhibitors Market, by Therapeutic Indication

  • 11.1. Cancer
    • 11.1.1. Hematological Cancers
      • 11.1.1.1. Leukemia
      • 11.1.1.2. Lymphoma
      • 11.1.1.3. Multiple Myeloma
    • 11.1.2. Solid Tumors
      • 11.1.2.1. Breast Cancer
      • 11.1.2.2. Lung Cancer
      • 11.1.2.3. Prostate Cancer
  • 11.2. Inflammatory Disorders
    • 11.2.1. Inflammatory Bowel Disease
    • 11.2.2. Rheumatoid Arthritis
  • 11.3. Neurological Disorders
    • 11.3.1. Alzheimer's Disease
    • 11.3.2. Parkinson's Disease

12. Histone Deacetylase Inhibitors Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals
  • 12.3. Research Institutes

13. Histone Deacetylase Inhibitors Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Histone Deacetylase Inhibitors Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Histone Deacetylase Inhibitors Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Histone Deacetylase Inhibitors Market

17. China Histone Deacetylase Inhibitors Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AstraZeneca plc
  • 18.6. Bio-Techne Corporation
  • 18.7. Bristol Myers Squibb Company
  • 18.8. Curis Inc.
  • 18.9. Eisai Co. Ltd.
  • 18.10. Huya Bioscience International LLC
  • 18.11. Italfarmaco S.p.A.
  • 18.12. Karyopharm Therapeutics Inc.
  • 18.13. Karyopharm Therapeutics Inc.
  • 18.14. Medivir AB
  • 18.15. MEI Pharma Inc.
  • 18.16. Merck KGaA
  • 18.17. Novartis AG
  • 18.18. Shenzhen Chipscreen Biosciences Co., Ltd.
  • 18.19. Shuttle Pharma
  • 18.20. Syndax Pharmaceuticals Inc.
  • 18.21. Thermo Fisher Scientific, Inc.
  • 18.22. Tokyo Chemical Industry Pvt. Ltd.
  • 18.23. Xynomic Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC3 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC3 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC3 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC8 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC8 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC8 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC5 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC5 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC5 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC6 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC6 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC6 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC7 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC7 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC7 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SIRTUIN1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SIRTUIN1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SIRTUIN1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SIRTUIN2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SIRTUIN2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SIRTUIN2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SIRTUIN3 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SIRTUIN3 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SIRTUIN3 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS IV, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC11 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC11 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HDAC11 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY PAN-HDAC INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY PAN-HDAC INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY PAN-HDAC INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INTRAVENOUS (IV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INTRAVENOUS (IV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS IV, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS IV, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS IV, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS IV, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS IV, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS IV, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS IV, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS IV, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS IV, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 288. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 289. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2018-2032 (USD MILLION)
  • TABLE 290. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2018-2032 (USD MILLION)
  • TABLE 291. GCC HISTONE DEACETYLASE INHIBITORS MARKE